Metastatic Disease Clinical Trial
Official title:
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid
NCT number | NCT04492735 |
Other study ID # | PSORC ICG |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 5, 2020 |
Est. completion date | June 2025 |
Use of indocyanine green will augment the accuracy of identification and resection of both
primary solid malignancies as well as their pulmonary metastases, where applicable We will
conduct a prospective feasibility study of pediatric patients with solid malignancies with or
without lung metastatases who present at the time of initial diagnosis or relapse. These
patients will receive a targeted dye to aid in the resection of these metastases. We plan to
assess ICG as it relates to:
1. Diagnostic accuracy using pathologic correlation as gold standard measure
2. Short and long term event free and overall survival
Status | Recruiting |
Enrollment | 45 |
Est. completion date | June 2025 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 45 Years |
Eligibility |
Inclusion Criteria: All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions. Diagnosis of primary or metastatic malignancy will be made by combination of: 1. Clinical evaluation and physical exam 2. Radiologic study including ultrasound, CT scan, and/or MRI 3. Pathologic diagnosis after biopsy Exclusion Criteria: 1. Those patients and parents/guardians unwilling to provide consent/assent. 2. Pregnant and/or women who are breast feeding. 3. Patients with Iodine allergies |
Country | Name | City | State |
---|---|---|---|
United States | Cincinnati Childrens Hospital Medical Center | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
Roshni Dasgupta |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy using pathologic correlation as gold standard measure | 2 years | ||
Primary | Short and long term event free and overall survival | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01450683 -
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
|
Phase 2 | |
Terminated |
NCT04116164 -
Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
Early Phase 1 | |
Completed |
NCT04595032 -
MAnagement of METastatic Disease In Campania (MAMETIC)
|
||
Terminated |
NCT01020305 -
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02496832 -
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
|
N/A | |
Completed |
NCT01763970 -
Stereotactic Radiation Therapy for Pediatric Sarcomas
|
N/A | |
Completed |
NCT01703910 -
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
|
Phase 2 | |
Completed |
NCT00609401 -
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
|
Phase 2 | |
Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
Completed |
NCT00480389 -
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
|
Phase 2 | |
Recruiting |
NCT03632005 -
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery
|
N/A | |
Terminated |
NCT02175654 -
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
|
Phase 2 | |
Not yet recruiting |
NCT01861938 -
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01875380 -
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Terminated |
NCT00532454 -
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
|
Phase 2 | |
Terminated |
NCT02795819 -
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
|
Phase 1 | |
Recruiting |
NCT05188911 -
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
|
||
Completed |
NCT03823989 -
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
|
Phase 1 | |
Terminated |
NCT01904916 -
CPCT-05 Biopsy Protocol Patient Selection
|
N/A | |
Terminated |
NCT01484860 -
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
|
Phase 2 |